Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Collection Kit used for collection, transport, and storage of fecal specimens for nucleic acid analyses; and GA-map Covid-19 Fecal Test, a non-invasive test with an easy-to-use home sampling procedure. Further, it offers laboratory services; and bioinformatic analysis services. The company develops rapid microbiome-based PCR test. Genetic Analysis AS was founded in 2008 and is headquartered in Oslo, Norway.
Norwegian Market Performance
7D7 Days: -0.4%
3M3 Months: 5.7%
1Y1 Year: 6.9%
YTDYear to Date: 4.8%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. More promisingly, the market is up 6.9% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.